CIBC Private Wealth Group
PTGX icon

CIBC Private Wealth Group’s Protagonist Therapeutics PTGX Stock Holding History

CIBC Private Wealth Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.14K Buy
+13
New +$1.06K ﹤0.01% 2894

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CIBC Private Wealth Group's PTGX Position: Q4 2025 in Review

CIBC Private Wealth Group opened a new position in Protagonist Therapeutics (PTGX) in Q4 2025: 13 shares worth $1.14K. The stake represents ﹤0.01% of the portfolio and ranks #2894 among its holdings.

316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • CIBC Private Wealth Group held 13 shares of Protagonist Therapeutics worth $1.14K as of Q4 2025.
  • Protagonist Therapeutics was a new CIBC Private Wealth Group position in Q4 2025.
  • Protagonist Therapeutics made up ﹤0.01% of CIBC Private Wealth Group's portfolio in Q4 2025, its #2894 holding.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on CIBC Private Wealth Group's 13F filing for Q4 2025, filed 12 Feb 2026.